Safety and Efficacy of the Subcutaneous Implantable Defibrillator  by Lewis, Geoffrey F. & Gold, Michael R.
Listen to this manuscript’s
audio summary by
JACC Editor-in-Chief
Dr. Valentin Fuster.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 6 7 , N O . 4 , 2 0 1 6
ª 2 0 1 6 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O UN DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 1 1 . 0 2 6REVIEW TOPIC OF THE WEEKSafety and Efﬁcacy of the
Subcutaneous Implantable Deﬁbrillator
Geoffrey F. Lewis, MD, Michael R. Gold, MD, PHDABSTRACTFro
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MaMultiple randomized, multicenter trials have established the role of the implantable cardioverter-deﬁbrillator (ICD) in the
treatment and prevention of sudden cardiac death. However, transvenous ICD leads have signiﬁcant short- and long-term
complications, offsetting some of the beneﬁt of this therapy. This has led to the development of the entirely subcu-
taneous ICD. This system is safe and effective, avoiding the need for intravascular leads. It is best suited for patients at
low risk for pacing and increased risk for transvenous lead complications. Ongoing randomized and long-term registries
will help identify the optimal role of this device in clinical practice. (J Am Coll Cardiol 2016;67:445–54)
© 2016 by the American College of Cardiology Foundation.D espite advances in medical therapy, suddencardiac death (SCD) remains a leading causeof cardiovascular mortality worldwide. The
implantable cardioverter-deﬁbrillator (ICD) is the
most effective treatment to date for either primary
or secondary prevention of SCD when utilized in con-
cert with appropriate medical therapy. ICDs reduce
mortality and are cost-effective in speciﬁc patient
populations that are at increased risk (1–5). Contem-
porary ICD systems typically consist of transvenous
intracardiac leads and a subcutaneous, pectoral pulse
generator to provide deﬁbrillation and pacemaker
capabilities.
Despite their proven efﬁcacy and relative safety,
potential short- and long-term complications are
associated with these devices, including infection,
pneumothorax, venous thrombosis, lead dislodge-
ment, lead malfunction, and lead perforation (6). A
recent meta-analysis of randomized clinical trials
ﬁnds the following complication rates related to de-
vice implant: pneumothorax, 1.1%; hematoma, 1.2%;
lead dislodgement, 3.1%; and infection, 1.5% (7).
Other studies of real-world implants have found
complication rates of 0.16% and 0.12% for lead
perforation and pericardial tamponade, respectivelym the Division of Cardiology, Medical University of South Carolina,
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nuscript received October 28, 2015; accepted November 5, 2015.(8). The 10-year transvenous lead failure rate is as
high as 20% (9). Moreover, due to anatomic or struc-
tural abnormalities (e.g., congenital heart diseases,
mechanical heart valves, or other rare situations),
certain patients are unable to have a traditional ICD
placed (10,11). Although complication rates with
transvenous ICD implantation are generally low, they
contribute to the morbidity and, possibly, mortality
of the procedure and may reduce its utilization.
Alternative implantable device options for pre-
vention of SCD have been developed. Epicardial or
pericardial patches do not require intravascular
access, but are infrequently used because of the need
for thoracotomy for placement and high failure rates
(12). Until recently, no other permanent substitute for
the traditional ICD was available. Beginning more
than a decade ago, an entirely subcutaneous
implantable cardioverter-deﬁbrillator (S-ICD) was
developed and later became commercially available.
The S-ICD (Boston Scientiﬁc, Marlborough, Massa-
chusetts) consists of a pulse generator and single lead
with a shock coil. The pulse generator is implanted in
the left lateral position, between the anterior and
mid-axillary lines near the apex of the left ventricle. A
single lead for sensing and deﬁbrillation is tunneledCharleston, South Carolina. Dr. Gold has received
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ATP = antitachycardia pacing
CRT = cardiac
resynchronization therapy
DFT = deﬁbrillation threshold
ICD = implantable
cardioverter-deﬁbrillator
SCD = sudden cardiac death
S-ICD = subcutaneous
implantable cardioverter-
deﬁbrillator
SVT = supraventricular
tachycardia
VF = ventricular ﬁbrillation
VT = ventricular tachycard
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446from the lateral pocket medially to the xi-
phoid process and subsequently cephalad
and is usually positioned 1 to 2 cm to the left
of and parallel to the sternum, with the distal
tip near the manubriosternal junction (13).
The lead consists of sensing electrodes at the
subxiphoid (proximal) and manubriosternal
junction (distal) positions, separated by an
8-cm shocking coil (Figure 1). Using the pulse
generator as a third electrode provides 3 po-
tential sensing vectors (pulse generator to
proximal or distal electrode and distal to
proximal electrode). The shock vector is from
pulse generator to coil and is reversed if more
than 1 shock is needed to terminate an
arrhythmia. The S-ICD lacks functionality forbradycardia or antitachycardia pacing, but can pro-
vide up to 30 s of post-shock transthoracic pacing
(14).
When considering the results of S-ICD clinical tri-
als, it is notable that the patient populations were
typically younger, with less advanced heart disease,
and often with “niche” indications, including chan-
nelopathies, previous ICD infection, or congenital
heart disease. In early trials, the mean age ranged
from 33 to 56 years (15–21). In trials reporting any
channelopathy patients, rates ranged from 10% to
28% (15,17,20,22–24). Although these important
groups are often viewed as the primary target popu-
lation for the S-ICD, they may not provide an accurate
basis for comparison with the common primary and
secondary prevention ICD populations.
The largest cohort for comparison to real-world ICD
patients is the pooled data from the IDE (Investiga-
tional Device Exemption) study and the EFFORTLESS
(Evaluation oF FactORs ImpacTing CLinical Outcome
and Cost EffectiveneSS of the S-ICD) registry (23).
This diverse population includes 882 patients
receiving ICDs. Primary prevention patients made up
69.9% of the study, and overall mean ejection frac-
tion (EF), including secondary prevention patients,
was 39.4  17.6%. Mean age was 50.3  16.9 years.
Overall, even this patient population is younger and
consists of more patients with preserved EF than
most transvenous ICD trials. On the basis of these
experiences, a recent paper proposes that excellent
candidates for the S-ICD include young patients
and those with limited vascular access, channelo-
pathies, congenital heart disease, and prior infection
of transvenous ICD; whereas poor candidates in-
clude those with indications for pacing, with mono-
morphic ventricular tachycardia (VT) amenable to
antitachycardia pacing (ATP), who are cardiac
resynchronization therapy (CRT)-eligible, and those
iafailing pre-implant screening (25). Recently published
case series have shown the S-ICD to be a safe and
effective alternative in dialysis patients, a prototypi-
cal population with limited vascular access (26,27).
The S-ICD received CE Mark approval in Europe in
2008, largely on the basis of small early trials (15). As
a result of the IDE trial (21), U.S. Food and Drug
Administration approval followed in 2012. World-
wide, >3,000 S-ICD systems were implanted in 2013
(28) and with >10 years of aggregate experience,
larger patient cohorts are now being examined.
SAFETY
Avoidance of risks associated with the procedure and
long-term presence of intravascular leads was a major
driving force in development of the S-ICD. The
structure of the S-ICD lead differs signiﬁcantly from a
transvenous ICD lead. Finally, development of
advanced discrimination algorithms in the S-ICD has
decreased the inappropriate shock rate for supra-
ventricular arrhythmias signiﬁcantly.
INFECTION. Signiﬁcant problems associated with
early S-ICD implants included device infection, lead
migration, and, to a lesser extent, implant-site
hematoma and device erosion. In the trial culmi-
nating in European CE Mark approval, only 2 of 55
(3.6%) devices became infected (15). Subsequent
descriptions of real-world clinical experience de-
monstrated signiﬁcantly higher infection rates. In
2012, Jarman et al. (19) and Olde Nordkamp et al. (17)
reported device infection in 11 of 111 (9.9%) and in 7
of 118 implants (5.9%), respectively. Others reported
lower device infection rates, ranging from 0% to 3.2%,
with the highest reported percentage being a single
device infection among only 31 patients (16,18,20).
The U.S. IDE trial reported 18 suspected or conﬁrmed
infections among 330 implants (5.5%) (Table 1) (21).
Only 4 of these patients required device explant, and
the others were deemed to be only superﬁcial in-
fections. There was a decreasing incidence with
greater operator and institutional experience, con-
sistent with a “learning curve,” resulting in an infec-
tion rate comparable to that of transvenous ICDs,
reported as 0.13% to 1.9% (29,30). Early results of the
EFFORTLESS S-ICD registry are similar: 18 of 472
(3.8%) patients had documented or suspicion of
infection related to the S-ICD procedure (24); 10
patients (2.1%) required device explant; and only 3
institutions had multiple cases of infection requiring
device removal. Over 5.8 years of follow-up, the
European Regulatory Trial cohort had 1 device
infection necessitating removal (31). Although all
hardware-related infections have the potential to
FIGURE 1 Postero-Anterior and Lateral Chest Radiographs of
an Implanted S-ICD
S-ICD ¼ subcutaneous implantable cardioverter-deﬁbrillator.
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447become systemic and life threatening, an important
distinction between transvenous and subcutaneous
ICD infections is their association with endocarditis
and bacteremia, which were reported in 22% to 54% of
transvenous ICD infections (32,33). None of the S-ICD
infections reported in the IDE trial and EFFORTLESS
registry were associated with endocarditis or bacter-
emia (21,24). As with transvenous ICDs, S-ICD–related
infections require individualization of care to deter-
mine in which circumstances device explant or other
invasive management is necessary.
IMPLANT SITE COMPLICATIONS. Less common compli-
cations related to S-ICD implant include hematoma
and device erosion. Reports of hematoma at the de-
vice implant site are rare in published case series.
Köbe et al. (20) report a single hematoma among 69
S-ICD implants (20). Early results of the EFFORTLESS
S-ICD registry report only a single hematoma in 472
patients (0.2%) evaluated over a mean of 558 days of
follow-up (24). Multiple other cohorts, including the
large IDE trial, report no implant-related hematomas
(15–19,21). Hematoma formation rates with the S-ICD
compare favorably with traditional ICD hematoma
rates of 0.86%, as reported in the National Cardio-
vascular Data Registry, and 1.2% to 2.4% in random-
ized clinical trials (7,34,35). Device erosion, a feared
complication due to the associated risk of infection
and potential need for additional invasive pro-
cedures, has also been reported with S-ICD implan-
tation. This is suggested to result from the large size
of the pulse generator and/or the implant location in
the axilla. An early experience by Jarman et al. (22)
reported an alarming 18.8% (3 of 16) rate of device
erosion. However, other cohorts have not reproduced
this high device erosion rate. Among the minority of
trials reporting any cases of pulse generator erosion,
rates ranged from 1.7% to 1.8% (17,19). Nonetheless,
the size of the ﬁrst-generation S-ICD’s pulse gener-
ator has clearly been an issue. The generator has a
volume of 69.9 cc, weighs 165 g, and measures 78.2 
65.5  15.7 mm. Each of these measurements is larger
than a comparable transvenous ICD. This large size,
particularly the thickness, has been problematic for
some patients, primarily those of smaller body
habitus. The second-generation S-ICD pulse gener-
ator has a smaller volume (59.5 cc), and weight
(130 g); itmeasures 83.169.1 12.7mm (36) (Figure 2).
Although the reduced pulse generator size may result
in decreased incidence of pulse generator erosion,
there is, as yet, no published data on this topic.
Recently published data from the combined
IDE and EFFORTLESS registries demonstrate the
learning curve associated with S-ICD implants (37).Complication rates decreased signiﬁcantly between
operators with the least (9.8%) and most (5.4%)
experience, and seem asymptotic after 13 implants.
S-ICD LEAD. The requirement for transvenous leads
has been described as the “Achilles’ heel” of tradi-
tional ICDs; thus, its avoidance is a major advantage
of the S-ICD (38). Utilization of a subcutaneous lead
circumvents difﬁculties with transvenous lead im-
plantation in patients with altered vascular or cardiac
anatomy, such as those with obstructed venous sys-
tems or congenital heart disease. Lead migration was
identiﬁed as an early and repetitive difﬁculty with
the S-ICD, often requiring lead revision, thus
exposing the patient to additional risk and causing
TABLE 1 Summary of S-ICD Trials
Bardy
et al. (15)
(n ¼ 55)
Dabiri Abkenari
et al. (16)
(n ¼ 31)
Aydin
et al. (18)
(n = 40)
Jarman
et al. (22)
(n ¼ 111)
Olde Nordkamp
et al. (17)
(n ¼ 118)
Köbe
et al. (20)
(n ¼ 69)
Weiss
et al. (21)
(n ¼ 330)
Lambiase
et al. (24)
(n ¼ 472)
Burke
et al. (23)
(n ¼ 883)
Age, yrs 56  13 53  4 42  15 33 NA 46  16 52  16 49  18 50  17
Male 80 77 70 NA 75 72 74 72 72.5
Follow-up 10  1 months 286 days 229 days 12.7  7.1 months 18  7 months 217  138 days 330 days 558 days 651  345 days
Ischemic cardiomyopathy 37 (67.0) 18 (58.0) 9 (22.5) 15 (14.0) 45 (38.0) 11 (15.9) 137 (41.4) 166 (37.0) 330 (37.8)
LVEF 35  14 38  15 47  15 NA 41  15 46  16 36  16 42  19 39  18
Primary prevention 43 (78.0) 21 (67.0) 17 (42.5) 55 (50.0) 71 (60.0) 41 (59.4) 262 (79.0) 282 (63.0) 610 (69.9)
Inappropriate shocks 5 (9.0) 5 (16.0) 2 (5.0) 17 (15.0) 15 (13.0) 3 (4.0) 41 (13.0) 32 (7.0) 14 (2.5)
Appropriate therapy
(% successful)
3 (100.0) 4 (100.0) 4 (96.4) 13 (100.0) 8 (100.0) 3 (100.0) 21 (95.2) 33 (100.0) 111 (98.2)
Complications
Infection 2 (3.6) 1 (3.2) 0 11 (9.9) 7 (5.9) 1 (1.4) 18 (5.6) 11 (2.3) 14 (1.5)
Lead migration 6 (10.9) 2 (6.4) 0 0 3 (2.5) 0 0 4 (0.8) 7 (0.8)
Device erosion 0 0 0 2 (1.8) 2 (1.7) 0 0 4 (0.8) 12 (1.4)
Hematoma 0 0 0 0 0 1 (1.4) 0 1 (0.2) 4 (0.4)
Patient characteristics
Ischemic cardiomyopathy 37 (67.0) 18 (58.0) 9 (22.5) 15 (14.0) 45 (38.0) 11 (15.9) 137 (41.4) 166 (37.0) 330 (37.8)
Dilated cardiomyopathy 10 (18.0) 4 (13.0) 9 (22.5) 5 (5.0) 30 (25.4) 25 (36.2) NA 43 (9.1) 277 (31.8)
HOCM NA NA 5 (12.5) 22 (20.0) NA 10 (14.5) NA 58 (12.2)
Congenital heart disease 2 (4.0) NA NA 13 (12.0) 1 (0.8) 3 (4.4) NA 33 (7.0)
Brugada syndrome NA 2 (6.5) NA 14 (13.0) NA NA NA
Idiopathic VT/VF NA 5 (16.1) 12 (30.0) 17 (15.0) 15 (13.0) NA NA 34 (8.0) 40 (4.6)
Ventricular noncompaction NA 1 (3.0) NA NA NA NA NA
Valvular heart disease NA 1 (3.0) 1 (2.5) NA NA NA NA
Long QT NA NA NA 10 (9.0) NA NA NA
CPVT NA NA NA 7 (6.0) NA NA NA
Inherited channelopathy 5 (16.1) 31 (27.9) 27 (23.0) 14 (20.3) 60 (13.0) 90 (10.3)
Other 6 (11.0) NA 13 (32.5) 13 (12.0) 57 (48.0) NA NA 14 (2.9)
Values are mean  SD, %, or n (%).
CPVT ¼ catecholaminergic polymorphic ventricular tachycardia; HOCM ¼ hypertrophic obstructive cardiomyopathy; LVEF ¼ left ventricular ejection fraction; NA ¼ not available; S-ICD ¼ subcutaneous
implantable cardioverter-deﬁbrillator. VF ¼ ventricular ﬁbrillation; VT ¼ ventricular tachycardia.
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448inappropriate ICD shocks due to myopotentials and
T-wave oversensing (15–22). In response to lead
migration issues, the manufacturer introduced a su-
ture sleeve to secure the lead at the xiphoid incision
that has essentially eliminated the incidence of this
complication. The EFFORTLESS registry found only
4 episodes of lead migration among 472 patients
(0.85%) (24).
S-ICD lead structure differs from traditional leads
in ways that confer advantages in durability and lead
failure. The 10-year transvenous ICD lead failure rate
is approximately 20% (9). Previous extravascular ICD
leads, such as epicardial patches, also have high
failure rates, but are structurally unique (12). Because
the S-ICD lead does not require a stylet for placement,
it has no central lumen, which provides greater ten-
sile strength. Furthermore, due to its subcutaneous
location, the S-ICD lead is less exposed to environ-
mental stress. Given that lead failures typically do not
appear for several years after implant, real-world
experience of long-term survival of the S-ICD lead isneeded. The longest follow-up reported to date is 5.8
years in the European Regulatory Trial, during which
there were no reported lead malfunctions or failures
(31). If the S-ICD lead proves more durable, repeat
invasive procedures and other complications associ-
ated with lead failure (e.g., inappropriate shocks and
malfunctions in pacing or sensing function) could be
reduced. Clearly, even longer-term follow-up is
necessary before ﬁrm conclusions regarding S-ICD
lead durability can be drawn, although the short and
intermediate follow-up data are very encouraging.
INAPPROPRIATE SHOCKS. Delivery of inappropriate
shocks due to errors in arrhythmia discrimination or
oversensing was observed repeatedly in early S-ICD
studies. The ﬁrst trials and patient cohorts reported
inappropriate shock rates of 5% to 25% (15–22).
Traditional ICDs have inappropriate shock rates <5%
(39). Inappropriate shocks in early trials were often
due to T-wave oversensing, lead migration, or supra-
ventricular tachycardias (SVTs). Introduction of the
suture sleeve effectively eliminated lead migration, as
FIGURE 2 Photograph of Lateral Views of First-Generation S-ICD, Second-Generation
(Emblem) S-ICD, and Single-Chamber ICD Pulse Generators Demonstrating
Device Thickness
S-ICDTM System EMBLEMTM S-ICD System Single Chamber ICD
ICD ¼ implantable cardioverter-deﬁbrillator; S-ICD ¼ subcutaneous implantable
cardioverter-deﬁbrillator.
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449discussed earlier. A software update with improved
SVT discrimination and device reprogramming has
reduced the incidence of inappropriate shocks due to
SVT and T-wave oversensing. Early versions of the
S-ICD were programmed with a shock-only zone at a
relatively low rate (180 beats/min). Current nominal
device settings include a conditional zone, which ap-
plies SVT discriminators, and a shock zone for rates
>220 beats/min. These changes reﬂect the ﬁndings
of the prospective, multicenter START (Subcutaneous
versus Transvenous Arrhythmia Recognition Testing)
trial, which compared discrimination algorithms of
the S-ICD with traditional transvenous ICD systems
(14). In the START trial, patients undergoing dual- or
tri-chamber transvenous ICD implant had both cuta-
neous (corresponding with S-ICD sensing vectors) and
transvenous electrograms recorded during induced
supraventricular and ventricular arrhythmias. Signals
were interpreted ofﬂine by the S-ICD and traditional
ICDs. The S-ICD discrimination algorithm includes 3
double-detection algorithms to prevent double
counting, morphology comparison to stored sinus
rhythm template, analysis of beat-to-beat mor-
phology changes, and comparison of QRS width to a
sinus template. The S-ICD was found to have 100%
sensitivity for appropriate detection of VT and ven-
tricular ﬁbrillation (VF). Additionally, using dual-zone
programming, the S-ICD had 98% speciﬁcity for
appropriately withholding therapy for SVT. Usage of
dual-zone programming has been found to increase
with operator experience, thus resulting in a reduc-
tion in inappropriate shock rate (37). The speciﬁcity of
transvenous ICDs was inferior to that of the S-ICD
(13,14). Despite the very low incidence of inappro-
priate shocks from supraventricular arrhythmias,
T-wave oversensing leading to inappropriate therapy
remains problematic with the S-ICD. The incidence
has been reduced with the use of pre-implant elec-
trocardiographic screening, although this screening
makes approximately 8% of patients ineligible to
receive an S-ICD (40). Use of the S-ICD sensing algo-
rithm has been proposed as a pre-implant screening
device to increase speciﬁcity, thus reducing inappro-
priate shocks (41). Exercise testing during pre-implant
screening has been suggested for all patients (42)
and is effective in establishing the preferred sensing
vector and lead placement in hypertrophic cardio-
myopathy patients (43). T-wave inversions resulting
from ischemia or left ventricular hypertrophy make
a patient 23 more likely to fail screening. Very large
or very small QRS complexes can also lead to
screening failure. Patients who experience T-wave
oversensing after implant can most often be managed
noninvasively through device programming (20,24).A recent revision of the discrimination algorithm
should further reduce such inappropriate shocks (44).
A less common cause of inappropriate shocks is
change in QRS morphology after the sinus rhythm
template is acquired at implant, such as development
of right bundle branch block. This can typically be
managed noninvasively by acquiring a new QRS
morphology template that the device uses for com-
parison during arrhythmia episodes. With the soft-
ware and programming updates in recent versions of
the S-ICD, inappropriate shock rates appear compa-
rable to that of transvenous ICDs, although there has
been no head-to-head comparison in equivalent pa-
tient populations. The EFFORTLESS registry, primar-
ily using dual-zone programming and higher shock
cutoff rates, reports inappropriate shock rates of 7%
(24). Traditional ICD registries report inappropriate
shock rates of 4% to 18% (45–47). However, newer
transvenous device algorithms have shown lower
inappropriate shock rates. The ADVANCE III (Avoid
Delivering Therapies for Nonsustained Arrhythmias
in ICD Patients III) trial, for example, randomized ICD
patients to standard (18 of 24) or prolonged (24 of 30)
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450intervals for detection of ventricular arrhythmia prior
to delivery of therapy (48). The prolonged interval
strategy resulted in less therapy (ATP or shock),
equivalent mortality, and reduced the inappropriate
shock rate from 11.6 to 5.1 per 100 patient-years.
LACK OF PACEMAKER/ATP FUNCTIONALITY. Mod-
ern ICDs are implanted not only for prevention of
SCD, but also, at times, for pacemaker and CRT
functions. A major limitation of the S-ICD is its lack of
pacemaker functionality, which eliminates it as an
option for patients with a requirement or high likeli-
hood for demand pacing. As CRT is an important
component of therapy for advanced heart failure,
CRT-eligible patients should not receive an S-ICD. In
the European Regulatory Trial cohort, followed for
5.8 years, 1 of 55 patients (1.8%) developed an indi-
cation for bradycardia pacing and had the S-ICD
explanted (31). In the same cohort, 2 of 55 patients
(3.6%) developed symptomatic heart failure and un-
derwent S-ICD explant in favor of a transvenous CRT
device (31). In such situations, consideration can be
given to concurrent use of the S-ICD with a trans-
venous pacemaker in lieu of S-ICD explant. This
approach was successfully used in small case series,
although careful assessment for “cross-talk” between
the devices is required (49,50). As there have been no
large studies of the safety and feasibility of this
approach, it should be used cautiously at this time. A
related issue is the inability to deliver ATP, when
indicated, in lieu of painful shocks. Both inappro-
priate and appropriate shocks increase mortality
among ICD patients (6,39). Clinicians may be apt to
consider a device incapable of ATP to be inferior.
However, previous trials may have overestimated the
incidence of ATP. An analysis of SCD-HeFT (Sudden
Cardiac Death in Heart Failure Trial) patients suggests
that approximately 15% of patients with New York
Heart Association functional class II to III heart failure
will experience monomorphic VT necessitating ATP
therapy over almost 45.5 months of follow-up (51).
This analysis also found that only 7% of the total
patient population received more than 1 shock for
high-rate monomorphic VT, a 1.8% per year risk.
Additionally, studies such as MADIT-RIT (Multicenter
Automatic Deﬁbrillator Implantation Trial–Reduce
Inappropriate Therapy) and ADVANCE III have shown
reduction in need for therapies with prolonged
detection intervals, due to spontaneous termination
of arrhythmia (39,48). Although this data suggests
that chances of requiring ATP therapy are generally
low, a signiﬁcant number of ICD patients may avoid
shock therapy via ATP, and this possibility should be
considered at time of implant.DEVICE LONGEVITY. Longevity is a concern with all
implantable devices, as device replacement exposes
the patient to risks related to infection and procedural
complications. All ICDs have limited battery life and
require pulse generator replacement once the battery
becomes depleted below a critical point. Manufac-
turer estimates of ﬁrst-generation S-ICD battery life
were approximately 5 years (52). Recently published
data from the European Regulatory Trial found a
median time to replacement of 5.0 years (31), with 71%
of S-ICD devices in service 5 years after implant. This
calculation included patients who had devices
removed for issues unrelated to battery life, including
replacement with transvenous ICD in 4 patients.
However, during the 5.8 years of follow-up, 5 of 55
patients (9%) required replacement within 1.5 years
due to premature battery depletion. The latest
single-chamber transvenous ICDs are predicted
to have a >10-year battery life (53); in this respect,
the S-ICD does not compare favorably. The
second-generation S-ICD is predicted to have a
7.3-year battery life (36); however, this manufacturer
claim has not been substantiated by real-world expe-
rience. Until battery life is equivalent to contempo-
raneous transvenous ICDs, the S-ICD will require more
frequent generator changes for battery depletion.
EFFICACY
Although the best measure of ICD efﬁcacy is the
number of lives saved from SCD, obtaining this in-
formation requires long-term follow-up studies that
are not yet available for a relatively new device such
as the S-ICD. Large, multicenter cohorts of patients
with S-ICDs are now underway that will provide ini-
tial information regarding real-world device efﬁcacy.
Deﬁbrillation threshold (DFT) testing, performed at
the time of device implant, is used to predict shock
efﬁcacy in the event of ventricular tachyarrhythmia.
The S-ICD delivers all shocks at 80 J and can reverse
polarity with each successive shock if more than 1 is
needed to terminate the arrhythmia (14). Figure 3
shows an example of successful detection and
termination of a VF episode. Because of the pulse
generator’s location in the lateral (as opposed to the
pectoral) position, the S-ICD has a more horizontal
shock vector than that of transvenous ICDs. A com-
parison of DFT testing in 49 patients undergoing
S-ICD versus transvenous ICD implant found a mean
DFT of 11.1 J in transvenous ICDs versus 36.6 J in
S-ICDs (15). Despite the larger absolute energy
requirement, because the S-ICD delivers an 80 J
shock, the absolute DFT safety margin was slightly
greater in the S-ICD. In the initial European clinical
FIGURE 3 S-ICD Stored Electrogram Showing Appropriately Detected and Treated Ventricular Fibrillation
The arrow at the discontinuity in the tracing represents the delivered shock. S-ICD ¼ subcutaneous implantable cardioverter-deﬁbrillator.
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451trial, the authors report 100% sensitivity for detection
of induced VF and 98% shock efﬁcacy (15). Similarly,
high efﬁcacy was noted in the IDE trial (21). If studies
continue to show such high efﬁcacy, it seems likely
that routine deﬁbrillation testing will not be needed
at implant.
Although these ﬁndings suggest that the S-ICD may
be as clinically effective at terminating arrhythmias as
traditional ICDs, DFT testing does not necessarily
correlate to real-world efﬁcacy. The PRAETORIAN
(Prospective, RAndomizEd comparison of subcu-
TaneOus and tRansvenous ImplANtable cardioverter-
deﬁbrillator therapy) randomized clinical trial will
provide a head-to-head comparison of traditional ICDs
and S-ICDs to establish their relative efﬁcacy (54).
Arrhythmia discrimination and resultant reduction
in the inappropriate shock rate is another important
measure of S-ICD efﬁcacy. Programming and dis-
crimination algorithms have evolved signiﬁcantly
since the introduction of the S-ICD. Early versions
were programmed with a shock-only zone at 180
beats/min, which led to unacceptably high rates of
shocks for sinus tachycardia and other SVTs. With
publication of the MADIT-RIT trial, there has been a
general move toward longer detection intervals andhigher cutoff rates (39). The START trial (discussed
earlier) showed the S-ICD to be equivalent or superior
to transvenous ICDs in arrhythmia detection and
discrimination (14). The publication of START led
to widespread use of dual-zone programming,
arrhythmia discriminators, and higher cutoff rates
with the S-ICD. Inappropriate shock rates markedly
decreased with these changes. Pooled data from the
IDE and EFFORTLESS trials shows an increase in
dual-zone programming from 51% to 95% and a con-
current 34% reduction in inappropriate shocks after
publication of START (24). Overall, with the adoption
of programming changes, the ability of the S-ICD to
avoid inappropriate shocks is equivalent to that of a
transvenous ICD.
Perhaps the most meaningful evaluation of S-ICD
efﬁcacy lies in its ability to convert spontaneous epi-
sodes of VT and VF. Early trials, although having low
rates of spontaneous arrhythmia, reported S-ICD
shock efﬁcacies between 95.2% and 100% (15–21).
Concerns have been raised regarding utility of the
S-ICD in certain channelopathy patients who, due to
typically younger age and lack of need for pacemaker
support, otherwise seem to be good candidates. A
speciﬁc example is Brugada syndrome patients, who
CENTRAL ILLUSTRATION A Comparison of Safety and Efﬁcacy of the S-ICD With Transvenous ICD
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452might experience T-wave oversensing due to dynamic
morphology changes (25). Although large group data
for this speciﬁc patient population are not available,
case reports found the S-ICD to effectively terminate
spontaneous arrhythmias and did not ﬁnd inappro-
priate shocks (55). The largest study available to date
incorporates pooled data from the IDE trial and early
results from the EFFORTLESS S-ICD database. This
dataset includes 882 patients and a mean of 651 days
of follow-up (23). Spontaneous VT/VF occurred in 59
patients, with a total of 111 events. Shock efﬁcacy for
these events was 90.1% and 98.2% for 1 and multiple
shocks (up to 5), respectively. These conversion rates
are comparable to those observed with transvenousICDs. Various trials have reported ﬁrst-shock efﬁcacy
of 83% to 90% with transvenous ICDs and overall
shock efﬁcacy of 97.3% to 99.6% (4,52,56). The pooled
data from IDE and EFFORTLESS showed an S-ICD
annual mortality rate of 1.6% and a 2-year mortality
rate of 3.2% (24). Mortality data are difﬁcult to
compare in light of the younger patients, higher EF
(mean 39%), and less advanced heart failure in the IDE
and EFFORTLESS population. Additionally, as with all
ICD trials, mortality is not only related to SCD. Taken
as a whole, the ﬁndings in this large patient population
suggest that S-ICDs and transvenous ICDs are equally
safe and clinically efﬁcacious in terminating sponta-
neous episodes of VT/VF.
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453CONCLUSIONS
With the ﬁrst S-ICD implants occurring >10 years
ago, there is a growing, although still incomplete,
worldwide body of evidence (in the absence of head-
to-head randomized trials) suggesting its non-
inferiority to traditional ICD systems with regard to
safety and efﬁcacy, with certain advantages of each
device type (Central Illustration). Although the
earliest implants were complicated by higher-than-
expected rates of infection, lead dislodgement, and
inappropriate shocks, the incidence of these events
has been markedly reduced by increased operator
experience and advances in implant technique and
device programming. The learning curve for individ-
ual operators was clearly demonstrated by the com-
bined IDE trial and EFFORTLESS registry results (37).
Patient populations in these early trials were unique,
due to the preponderance of young patients with
channelopathies, congenital heart disease, and other
rare conditions. In real-world clinical situations, the
S-ICD has >98% overall shock efﬁcacy for acute con-
version of VT/VF, equivalent to transvenous ICDs.
DFT testing has been highly successful with the S-ICD
and the absolute DFT margin is actually slightly
greater than with transvenous ICDs. Although avail-
able safety and efﬁcacy data for the S-ICD are veryencouraging, clinical trials including large numbers
are not yet available. In the coming years, data from
the complete EFFORTLESS ICD registry, the U.S. post-
marketing registry, and head-to-head performance
versus transvenous ICDs in the PRAETORIAN trial will
provide a great deal of additional information (24,54).
The UNTOUCHED (Understanding Outcomes With the
S-ICD in Primary Prevention Patients with Depressed
Ejection Fraction) study is a prospective registry of
primary prevention patients with reduced EF (57),
which will provide valuable data on this device in the
most common cohorts receiving ICDs. The second-
generation S-ICD has improvements, including
smaller generator size, longer battery life, and capa-
bilities for remote monitoring (36). With currently
available information, the S-ICD is an appealing
alternative to traditional ICDs for speciﬁc patient
populations in whom traditional ICD implant would
have greater risk or difﬁculty and, arguably, may
be considered for any patient undergoing ICD
implantation.
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